Invitae Saham

Invitae EBITDA

Delisted·7 Agu 2024

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Invitae (NVTAQ) pada 12 Agu 2026 adalah 175,45 Juta. USD. Tahun sebelumnya, EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah -704,65 Juta. USD — perubahan sebesar -124,90% (lebih tinggi).

EBITDA

175,45 Juta.USD

YoY

-124,90%

Terakhir Diperbarui:

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Invitae adalah 2026 175,45 Juta. USD. EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Invitae adalah 2025 -704,65 Juta. USD. Menurun -124,90% lebih tinggi dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Invitae Analisis saham

Apa yang dilakukan Invitae? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Invitae

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Invitae adalah 175,45 Juta. USD pada tahun 2026.

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari Invitae berubah dari -704,65 Juta. USD menjadi 175,45 Juta. USD, mewakili perubahan -124,90%. Nilainya lebih tinggi daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) Invitae sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

EBITDA mengukur kinerja operasional sebelum dampak struktur keuangan, lingkungan pajak, dan biaya penyusutan non-kas.

EBITDA = EBIT + Penyusutan & Amortisasi

USD EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak Invitae EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) secara historis dan real-time.

Access this data via the Eulerpool API

Laporan Laba Rugi — Invitae

Semua Metrik Kunci — Invitae